ALPS Advisors’s Maze Therapeutics MAZE Stock Holding History

ALPS Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Buy	55,970 +16,799	+43%	+$440K	0.01%	579
2026 Q1	$1.17M	Buy	+39,171	New	+$1.73M	0.01%	554
2025 Q4	–	Sell	-13,742	Closed	-$356K	–	1091
2025 Q3	$356K	Sell	13,742 -9,835	-42%	-$166K	﹤0.01%	933
2025 Q2	$289K	Buy	+23,577	New	+$245K	﹤0.01%	945

Other funds holding MAZE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

MGB

Mass General Brigham Somerville, Massachusetts $361M AUM

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

ALPS Advisors's MAZE Position: Q2 2026 in Review

ALPS Advisors increased its Maze Therapeutics (MAZE) stake by 43% in Q2 2026, buying an estimated $440K and bringing the position to 55,970 shares worth $1.67M. The position accounts for 0.01% of the portfolio, ranked #579.

ALPS Advisors first reported a position in MAZE in Q2 2025 and has held it in 4 quarters since. 39 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

ALPS Advisors held 55,970 shares of Maze Therapeutics worth $1.67M as of Q2 2026.
ALPS Advisors bought 16,799 Maze Therapeutics shares in Q2 2026, an estimated $440K.
Maze Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #579 holding.
ALPS Advisors first reported a position in Maze Therapeutics in Q2 2025 and has held it in 4 quarters since.
39 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.